NHTC- The NEXT FONX..and why..DD inside...
from Rb..
By: LLVBIRDIEMAN $$$
Reply To: 6846 by stockguru2001 $$$$ Thursday, 4 Oct 2001 at 11:20 AM EDT
Post # of 6852
I have information direct from the PR people that PR will start to hit soon. The PR will take us to convention time, (Nov 2, 2000) when things will really light up. The overhang of the preferred is gone, bought out by special group. This stock as a chance to run up to 15 cents in the next few weeks, with potential to go 50 cents or more in 6 months. Hang on for the ride. All the longs will be rewarded for hanging in there. Good luck to all.
...
Special Announcement
In recent days, we here at The MoneyLine Report have anguished over the events which occurred in New York City and Washington. With the temporary decline in the stock markets, it now has become more important than ever to provide our followers with shining stars in the OTC Markets. We are proud of our country and salute all Americans everywhere.
Breaking News On Natural Health Trends Corporation (OTC BB: NHTC)
NHTC ANNOUNCES RECORD REVENUES
WITH FEMALE VIACREME PRODUCT!!!
Informed investors take note! The MoneyLine Report has compiled impressive stats with this year's picks. We salute all who heeded our last recommendation OTCBB:NMMG, rising from .45 to over $2.50 In our daily research, rarely do we find a company as exciting as Natural Health Trends Corporation [OTCBB:NHTC]. We believe this could be our best recommendation of the year. We are giving (NHTC) our Highest Rating of STRONG-BUY- AGGRESSIVE GROWTH.
NHTC Chart
Natural Health Trends Corporation
OTC Bulletin Board
Strong Buy
OTCBB: NHTC
Strong Buy
Current Price: $0.04
52 Week High/Low: $0.15/$0.009
Target: $0.87
Shares Outstanding: 200,400,000
Float: 150,000,000
ABOUT THE COMPANY
Natural Health Trends Corporation is a holding company for two operating subsidiaries, ekaire.com, Inc., which sells nutritional supplements and vitamins and Lexxus International, Inc. Lexxus was acquired in January 2001 and markets and sells the revolutionary new product, Viacreme™. Viacreme™ was developed by a leading Gynecologist. These products contain the essential active ingredients to promote clitoral sensitivity and improve the opportunity for women to achieve greater sexual satisfaction.
REASONS TO OWN THE STOCK
The The MoneyLine Report is putting NHTC on our Strong Buy – Aggressive Growth recommendation list for the following reasons:
1. Lexxus International has earned an estimated $10 million in revenues in just its first six months of operation. The product, Viacreme™, has received considerable amounts of positive exposure, including appearances on Good Morning Canada, FOX News and EXTRA, a leading television news magazine program. The product was also mentioned as a potential solution for women's sexual dysfunction in Oprah Winfrey's popular women's magazine "O" (May 2001).
2. We have seen worldwide sales for Pfizers, Viagra, a leading manufacturer for a treatment for erectile dysfunction, increase 15% to $377 Million in the first quarter of 2001. According to their company’s website, their treatment is among the most widely prescribed medications in the world, with more than 40 million prescriptions having been written by more than 500,000 physicians for more than 13 million men worldwide. Since introducing Viagra in March 1998, the price of Pfizers’s (NYSE:PFE) stock has shot from $30 to $48 per share. Statistics have shown that the market for NHTC’s non-prescription 100% natural product for Women, Viacrème™, may be well over 100 million users.
3. NHTC believes that their product for women has twice the market potential of Pfizer’s product for men for the following reasons:
According to a study published in the February 10, 1999 issue of the Journal of the American Medical Association, 43% of women suffer from sexual dysfunction compared to only 31% of men.
23% of the male population is a candidate to use the top selling prescription for ED, while as many as 46% of women have expressed a desire for a product of that nature to their physicians. As stated previously, Pfizers sold over $1 billion dollars in its first year, with only 23% of the male population as potential consumers.
With no prescription needed and twice the market for their product, the Company believes they are in the position to gain extensive profits from the sale of the Viacrème™ product.
4. Natural Health Trends' products, include skin care items, antioxidants, ointments, and other remedies. Subsidiary, eKaire.com sells health care products through its multilevel marketing network of about 40,000 part-time and full-time independent salespeople. NHTC’s other subsidiary, Lexxus International, markets health products for women created to stimulate sex drive.
INVESTMENT CONSIDERATION
Fact: Each year, Americans spend over $67 billion on prescription drugs.
Fact: In the U.S. alone, over 5 million prescriptions for Viagra have been written in less than one year.
Fact: NHTC has over 28,000 independent distributors, having opened five countries including the United States, Canada, Puerto Rico, Australia and New Zealand in the past 5 months.
Based on current revenue streams and an expanding market, NHTC is projecting $100 million in revenues with $10 million to the bottom line within the next 12 months. This makes NHTC a stock with unprecedented growth. At a modest P/E ratio of 25/1, NHTC would be worth $1.25 per share. The MoneyLine Report is placing a conservative estimate of only $0.87 per share. They have an exclusive product and eager clients to buy it. Marketing for Viacreme™ is only in its beginning phases with already $10 Million in revenues generated. As NHTC broadens its market for their Viacrème™ product, this stock goes to $4 and beyond. NHTC is a superior company with tremendous upside potential! Don’t miss this opportunity.
--------------------------------------------------------------------------------
Charts Provided Courtesy Of BigCharts.com
--------------------------------------------------------------------------------
Click here to receive your FREE Membership to the The MoneyLine Report. Sign Up Today!
Disclaimer
The MoneyLine Report Newsletter is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. Moreover, as detailed below, this publication accepts compensation from certain of the companies which it features. To the degrees enumerated herein, this newsletter should not be regarded as an independent publication.
The MoneyLine Report has been paid the following fee by NHTC for a period of three months of representation: $60,000 cash by a third party on behalf of the company. The MoneyLine Report may from time to time buy or sell NHTC common shares in the open market without notice. The information contained in this report is not intended to be, and shall not constitute, an offer to sell or solicitation of any offer to buy any security. It is intended for information only. Some statements may contain so-called "forward-looking statements". Many factors could cause actual results to differ. Investors should consult with their Investment Advisor concerning NHTC.
All statements and expressions are the sole opinions of the editors and are subject to change without notice. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF THE SQUAWK PAGE.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at sec.govand the National Association of Securities Dealers ("NASD") at nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at sec.gov. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site. |
